Sars-cov-2 vaccines
US-2024408193-A1 · Dec 12, 2024 · US
Methods and compositions for inducing protective immunity against a Marburg virus infection
US10925955B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10925955-B2 |
| Application number | US-201716316846-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 11, 2017 |
| Priority date | Jul 15, 2016 |
| Publication date | Feb 23, 2021 |
| Grant date | Feb 23, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions, vaccines and methods using adenovirus vectors for priming and boosting vaccinations for inducing protective immunity against a Marburg virus infection are described.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of inducing an immune response against a Marburg virus in a subject, the method comprising: a. administering to the subject a first composition comprising an immunologically effective amount of a first adenovirus vector comprising a nucleic acid encoding a first antigenic protein of a Marburg virus having the amino acid sequence of SEQ ID NO:3; and b. administering to the subject a second composition comprising an immunologically effective amount of a second adenovirus vector comprising a nucleic acid encoding a second antigenic protein of a Marburg virus; wherein steps (a) and (b) are conducted in either order. 2. The method according to claim 1 , wherein the second adenovirus vector comprises a nucleic acid encoding an antigenic protein having the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO:4. 3. The method according to claim 1 , wherein the second adenovirus vector comprises a nucleic acid encoding an antigenic protein having the amino acid sequence of SEQ ID NO: 3. 4. The method according to claim 1 , wherein the adenovirus vectors are rAd26 or rAd35 vectors. 5. The method according to claim 1 , wherein step (b) is conducted 1-12 weeks after step (a).
Assignees
Inventors
Classifications
Immunostimulants · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
Viral vectors · CPC title
viral genome or elements thereof as genetic vector · CPC title
characterised by the dose, timing or administration schedule · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10925955B2 cover?
- Compositions, vaccines and methods using adenovirus vectors for priming and boosting vaccinations for inducing protective immunity against a Marburg virus infection are described.
- Who is the assignee on this patent?
- Janssen Vaccines & Prevention Bv
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).